Andrew Wilkinson

Andrew Wilkinson is an accomplished medicinal chemist with extensive experience in drug discovery and project leadership. Currently serving as a Research Leader in Medicinal Chemistry at INFEX Therapeutics since August 2017, Andrew successfully progressed a metallo-beta-lactamase inhibitor program from initial hits to preclinical candidate within two years. Prior to this, Andrew held various leadership roles at Redx Pharma and Almac Discovery, where significant contributions were made to the development of novel nuclear receptor modulators and oncology drug candidates. Andrew holds a PhD in Chemistry from Durham University, complemented by an MSci in Chemistry from the same institution.